Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity

Molecular Immunology

Volumn 47, Issue 4, 2010, Pages 816-824

  Lee, Seung Hyun ^a   Park, Dong Woon ^b   Sung, Eun Sil ^a   Park, Hye Ran ^b   Kim, Jin Kyoo ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Changwon National University   (South Korea)

Author keywords

Agonistic antibody; Apoptotic cell death; Death receptor 4; Humanization; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; DEATH RECEPTOR 4; EPITOPE; ISOLEUCINE; LEUCINE; MONOCLONAL ANTIBODY AY4 SINGLE CHAIN FRAGMENT VARIABLE; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVATION; HINGE REGION; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; TUMOR CELL; TUMOR CELL DESTRUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; CYTOTOXICITY, IMMUNOLOGIC; HCT116 CELLS; HUMANS; IMMOBILIZED PROTEINS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; KINETICS; MICE; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT;

MURINAE; MUS;

EID: 72949091664     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.09.041     Document Type: Article

References (33)

1. Adams C., Totpal K., Lawrence D., Marsters S., Pitti R., Yee S., Ross S., Deforge L., Koeppen H., Sagolla M., Compaan D., Lowman H., Hymowitz S., and Ashkenazi A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ. 15 (2008) 751-761
2. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
3. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat. Rev. Drug Discov. 7 (2008) 1001-1012
4. Cohen-Saidon C., Nechushtan H., Kahlon S., Livni N., Nissim A., and Razin E. A novel strategy using single-chain antibody to show the importance of Bcl-2 in mast cell survival. Blood 102 (2003) 2506-2512
5. Ewert S., Honegger A., and Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34 (2004) 184-199
6. Foote J., and Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol. 224 (1992) 487-499
7. Ganten T.M., Koschny R., Sykora J., Schulze-Bergkamen H., Buchler P., Haas T.L., Schader M.B., Untergasser A., Stremmel W., and Walczak H. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin. Cancer Res. 12 (2006) 2640-2646
8. Harbury P.B., Zhang T., Kim P.S., and Alber T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262 (1993) 1401-1407
9. Kabat E.A., and Wu T.T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J. Immunol. 147 (1991) 1709-1719
10. Kim D.S., Lee S.H., Kim J.S., Lee S.C., Kwon M.H., and Kim Y.S. Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting. Biochem. Biophys. Res. Commun. 379 (2009) 314-318
11. Kugler M., Stein C., Schwenkert M., Saul D., Vockentanz L., Huber T., Wetzel S.K., Scholz O., Pluckthun A., Honegger A., and Fey G.H. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework. Protein Eng. Des. Sel. 22 (2009) 135-147
12. Lee H.W., Kim T.I., Chan K.H., Kwon M.H., Kim J.S., Jin M., and Kim Y.S. Inducing rigid local structure around the zinc-binding region by hydrophobic interactions enhances the homotrimerization and apoptotic activity of zinc-free TRAIL. Biochem. Biophys. Res. Commun. 362 (2007) 766-772
13. Lee H.W., Lee S.H., Lee H.W., Ryu Y.W., Kwon M.H., and Kim Y.S. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem. Biophys. Res. Commun. 330 (2005) 1205-1212
14. Lefranc M.P., Giudicelli V., Ginestoux C., Jabado-Michaloud J., Folch G., Bellahcene F., Wu Y., Gemrot E., Brochet X., Lane J., Regnier L., Ehrenmann F., Lefranc G., and Duroux P. IMGT, the International ImMunoGeneTics information system. Nucleic Acids Res. 37 (2009) D1006-1012
15. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J., and Cohen G.M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 65 (2005) 11265-11270
16. Makabe K., Nakanishi T., Tsumoto K., Tanaka Y., Kondo H., Umetsu M., Sone Y., Asano R., and Kumagai I. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. J. Biol. Chem. 283 (2008) 1156-1166
17. Morris N.P., Peters C., Montler R., Hu H.M., Curti B.D., Urba W.J., and Weinberg A.D. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol. Immunol. 44 (2007) 3112-3121
18. Muhlenbeck F., Schneider P., Bodmer J.L., Schwenzer R., Hauser A., Schubert G., Scheurich P., Moosmayer D., Tschopp J., and Wajant H. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 275 (2000) 32208-32213
19. Natoni A., MacFarlane M., Inoue S., Walewska R., Majid A., Knee D., Stover D.R., Dyer M.J., and Cohen G.M. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 139 (2007) 568-577
20. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., and Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22 (2003) 2034-2044
21. Ozoren N., and El-Deiry W.S. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 4 (2002) 551-557
22. Pack P., Muller K., Zahn R., and Pluckthun A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol. 246 (1995) 28-34
23. Papenfuss K., Cordier S.M., and Walczak H. Death receptors as targets for anti-cancer therapy. J. Cell Mol. Med. 12 (2008) 2566-2585
24. Park K.J., Lee S.H., Kim T.I., Lee H.W., Lee C.H., Kim E.H., Jang J.Y., Choi K.S., Kwon M.H., and Kim Y.S. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 67 (2007) 7327-7334
25. Park K.J., Lee S.H., Lee C.H., Jang J.Y., Chung J., Kwon M.H., and Kim Y.S. Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death. Biochem. Biophys. Res. Commun. 382 (2009) 726-729
26. Park K.J., Park D.W., Kim C.H., Han B.K., Park T.S., Han J.Y., Lillehoj H.S., and Kim J.K. Development and characterization of a recombinant chicken single-chain Fv antibody detecting Eimeria acervulina sporozoite antigen. Biotechnol. Lett. 27 (2005) 289-295
27. Presta L.G., Chen H., O'Connor S.J., Chisholm V., Meng Y.G., Krummen L., Winkler M., and Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57 (1997) 4593-4599
28. Secchiero P., Milani D., Gonelli A., Melloni E., Campioni D., Gibellini D., Capitani S., and Zauli G. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and TNF-alpha promote the NF-kappaB-dependent maturation of normal and leukemic myeloid cells. J. Leukoc. Biol. 74 (2003) 223-232
29. Sung E.S., Park K.J., Lee S.H., Jang Y.S., Park S.K., Park Y.H., Kwag W.J., Kwon M.H., and Kim Y.S. A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol. Cancer Ther. 8 (2009) 2276-2285
30. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., Hill M., Mays T., McCoy T., Fox N.L., Halpern W., Corey A., and Cohen R.B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J. Clin. Oncol. 25 (2007) 1390-1395
31. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., and Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13 (2007) 1070-1077
32. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
33. Wu X., Li P., Qian C., Li O., and Zhou Y. Trimeric coiled-coil domain of human pulmonary surfactant protein D enhances zinc-binding ability and biologic activity of soluble TRAIL. Mol. Immunol. 46 (2009) 2381-2388